Farmacia
HOSPITALARIA
Órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria

ORIGINALS
Bilingual edition english/spanish

Clinical–economic impact of the change of protocol for use of basiliximab in liver transplant

Impacto clínico-económico del cambio de protocolo de uso de basiliximab en el trasplante hepático

Inmaculada Plasencia-García[1], Enrique Tévar-Alfonso[1], Antonio González-Rodríguez[2], Antonia Moreno-García[2], Javier Merino-Alonso[1], Armando Aguirre-Jaime[3]

[1]Pharmacy Unit. [2]Gastroenterology Unit. [3]Research Support Unit. Hospital Universitario Nuestra Señora de La Candelaria, Tenerife, Islas Canarias. Spain.

Author of correspondence
Inmaculada Plasencia García
Servicio de Farmacia.
Hospital Universitario
Nuestra Señora de La Candelaria.
Carretera General del Rosario 145,
38010, Santa Cruz de Tenerife, Canarias.

Email:
rguanipg@hotmail.com

How to cite this paper
Plasencia-García I, Tévar-Alfonso E, González-Rodríguez A, Moreno-García A, Merino-Alonso J, Aguirre-Jaime A. Clinical-economic impact of the change of protocol for use of basiliximab in liver transplant. Farm Hosp. 2019;43(1):13-8.

Abstract
Objective: Evaluation of the clinical and economic impact after the protocol change of basiliximab use in orthohepatic transplant.
Method: Retrospective study in which all liver transplant patients were included during the years 2013, 2014 and until February 15, 2015. The study was divided into two stages according to the protocol used: 1) administration of basiliximab only if factors of previous risk, and 2) administration of the first dose of basiliximab to all transplant patients and the second dose if it had risk factors.
Results: 83 patients were included, 34 according to protocol 1 and 49 according to protocol 2. No significant differences were found in the clinical variables evaluated or in the variables related to health outcomes. Considering that the percentage of patients without risk factors who received basiliximab was 43% and without differences in the stays, we could estimate an additional cost for the universal use of basiliximab in orthohepatic transplant of € 21,400.00.
Conclusions: In our population, the protocol change making universal the first dose of basiliximab has not shown the expected benefits, but an increase in costs, so the suitability of the new protocol in consensus with the medical team must be reconsidered. The evidence regarding the use of basiliximab in orthohepatic transplant remains limited and although its benefit seems clear in patients with risk factors, especially renal failure, recommendations about its use universally remains controversial.

Resumen
Objetivo: Evaluación del impacto clínico y económico tras el cambio de protocolo de uso de basiliximab en el trasplante ortohepático.
Método: Estudio retrospectivo en el que se incluyó a todos los pacientes trasplantados de hígado durante los años 2013, 2014 y hasta el 15 de febrero de 2015. El estudio se dividió en dos etapas según el protocolo empleado: 1) administración de basiliximab solo si existían factores de riesgo previos, y 2) administración de la primera dosis de basiliximab a todos los pacientes trasplantados y de una segunda dosis si existían factores de riesgo.
Resultados: Se incluyeron 83 pacientes, 34 según el protocolo 1 y 49 según el protocolo 2. No se encontraron diferencias significativas en las variables clínicas evaluadas ni en las variables relacionadas con los resultados en salud. Considerando que el porcentaje de pacientes sin factores de riesgo que recibieron basiliximab fue del 43% y sin diferencias en las estancias, podríamos estimar un coste adicional por el empleo universal de basiliximab en el trasplante ortohepático de 21.400 €.
Conclusiones: En nuestra población, el cambio de protocolo haciendo universal la primera dosis de basiliximab no ha mostrado los beneficios esperados, pero sí un aumento de los costes, por lo que debe replantearse la idoneidad del nuevo protocolo en consenso con el equipo médico. La evidencia en relación con el empleo de basiliximab en el trasplante ortohepático sigue siendo limitada y aunque parece claro su beneficio en pacientes con factores de riesgo, especialmente fallo renal, las recomendaciones acerca de su uso de forma universal sigue siendo controvertido.

Introduction

Liver transplant surgery is demanding, with plenty of bleeding, transfusions, and frequent use of vasoactive drugs which have a harmful effect on kidneys. Without induction, tacrolimus (TAC) must be initiated within the first 12 hours, with a patient still unstable. Additionally there is difficult dosing, which is complex during the first days, because it must be initiated with a weight-adjusted dose but with high variability between and among individuals. Acute renal damage will occur primarily because calcineurin inhibitors (CNIs) will cause vasoconstriction both in the afferent and efferent arteriole, therefore reducing the glomerular filtration rate (GFR), leading to higher morbidity with a prolonged stay at the ICU and requiring hemofiltration or dialysis. The chronic form of nephrotoxicity is characterized by the development of irreversible structural damage, which could lead to an end-stage renal disease[1]. For this reason, different strategies have been designed in an attempt to reduce it, such as the use of interleukin-2 antibodies (IL-2R) as immunosuppressants in the induction period, because no serum level monitoring is required, and it is considered effective and safe according to prospective or retrospective studies and randomized clinical trials, as well as having low immunogenicity[2,3]. In any case, it should always be used in combination with CNIs in order to prevent acute rejection[4,5].

Basiliximab is a chimeric monoclonal antibody binding specifically and with high affinity to the CD25 antigen of activated T-lymphocytes that express the high-affinity IL-2R receptor. This prevents IL-2 from binding to the receptor, which is a critical signal for T-cell proliferation in the cell immune response involved in organ rejection[2]. This is the only option available with the mechanism of action described, although in Spain it is only indicated as prophylaxis for acute rejection in renal transplant, and its used was included in the protocol according to Royal Decree 1015/2009 on Medications in Special Situations.

The infection rate (bacterial, viral and fungal) is similar among patients receiving basiliximab or daclizumab and placebo, including infections by cytomegalovirus. No differences have been observed in the number of *de novo* post-transplant neoplasias at one year of treatment[6,7]. Its main advantage is that there will be no impact on renal function or bone marrow and, therefore, it can be used for renal impairment, as well as in anemia, leukopenia or thrombocytopenia. The negative aspects are that their influence on the relapse of Hepatitis C is unknown, because bad evolution has been described regarding Hepatitis C relapse in patients treated with daclizumab and mycophenolate mofetil (MMF), with no confirmation by subsequent studies. However, with new antivirals currently available for Hepatitis C treatment and its high cure rate, it seems that this aspect might become less relevant[8,9].

There is a higher development of renal impairment immediately after liver transplant if the patient presented previous renal impairment, refractory ascites, malnutrition, an unfavorable prognostic index, and suboptimal donor; but many patients without these risk factors will also develop this complication[2].

Induction with basaliximab allows to delay CNI initiation up to 4-7 days after the transplant, according to the number of basiliximab doses administered. A CNI-free period of time is allowed, so that renal function can be recovered after the aggressions received during the perioperative period; this will be usually initiated in the ward when there is clinical stability. The target therapeutic levels for TAC during the first 6 weeks without basiliximab should be within 10-15 ng/mL, while with basiliximab these could be between 8-10 ng/mL, contributing to a lower nephrotoxicity at long term and, as it has been recently observed, lower recurrence of tumors in hepatocellular carcinoma[10,11].

Until 2013, the immunosuppression protocol in our center was based on the administration of basiliximab only to patients with risk factors: renal impairment previous to the transplant (GFR<60 mL/min/1.73 m^2 or serum creatinine [Cr]>1.5 mg/dL), renal impairment immediately after the transplant (within the first 48 hours), defined as oliguria<0.5 mL/kg/h, GFR<60 mL/min/1.73 m^2 or Cr elevation>1.5 mg/dL, or cirrhosis with refractory ascites and severe malnutrition with renal impairment present before the transplant. In patients who presented the risk factors described, the dose to be administered was two 20 mg perfusions on the day of the transplant, and 4 days after the transplant. The second dose might not be administered if at Day 4 the renal function of the patient continued stable (GFR>60 mL/min/1.73 m^2 or Cr<1,2 mg/dL and diuresis>1 mL/kg/h).

According to the current immunosuppression protocol with universal administration of basiliximab, implemented since 2014, all patients would receive a first 20 mg dose on the day of the transplant and a second 20 mg dose on the fourth day after the transplant, individualized according to the basal characteristics of the patient and their clinical evolution. The introduction of the calcineurin inhibitor is indicated between Days 5 to 7 for those who have received both doses, and on the 3rd-4th day if they have only received one dose.

With this change of strategy, it was expected to achieve a reduction in the time of ICU hospitalization and a lower morbidity of patients after the transplant. Our hypothesis if that this change of protocol has not led to the results expected in terms of reduction in hospital stays and better evolution in renal function; therefore, the objective of this study is to evaluate the clinical and economic impact after the change of protocol for use of basiliximab in orthotopic liver transplantation (OLT).

Methods

A retrospective observational study comparing two protocols, including all adult patients who underwent a liver transplant in a public hospital from January, 1st, 2014 to February, 15th, 2015, with follow-up during the first 12 months after the transplant. The study has been classified by the Spanish Agency of Medicines as EPA-OD (Post-authorization study, other designs), and approved by a Research Ethics Committee.

The study was conducted with two types of patients: those who underwent a liver transplant during 2013, following the protocol in place until that date, and those who underwent a transplant in 2014-2015, according to the protocol adopted in 2014. In both cases, immunosuppressant therapy included the introduction of MMF on Day 1 after the transplant, with corticosteroids.

The data collection logbook included age, gender, year of the transplant, basiliximab doses administered, days for the initiation of treatment with TAC, days of ICU stay, days of stay for the episode, creatinine and renal function previous to transplant, at ICU discharge, at hospital discharge, and one year after transplantation, mortality within the post-operative period before discharge, at three months and one year, presence of diabetes and refractory ascites before the transplant, hypertension and diabetes as post-transplant complications, and the Model for End-stage Liver Disease (MELD) Scales[12].

Post-transplant hypertension was defined as the need for hypertension treatment or change from the treatment previous to transplant; and post-transplant diabetes was defined as the need for insulin or change of antidiabetic treatment regimen vs. previous home treatment.

Renal dysfunction was defined as GFR, calculated according to MDRD4, below 60 mL/min/1.73 m^2.

Anthropometric data, use and cost of basiliximab vials, days of initiation for TAC treatment, and stay at ICU and for the episode, were obtained from the Farmatools® program at the Pharmacy Unit.

The lab test and clinical data, post-transplant complications, and MELD scale, were obtained from the Selene® Electronic Clinical Record program.

Costs per stay at ICU and hospital ward are the public prices by the Regional Health System.

The sample of this study has been limited to the number of transplants conducted during the periods of time compared. The 34 patients from the previous protocol and 49 from the new one allowed to detect relevant differences of at least 35%, and mean or median differences of at least 18 units, with an 80% power in bilateral hypothesis testing at a p≤0.05 significance level.

The sample characteristics were described by summarizing the nominal variables with the relative frequency of their component categories, the scale ones that do not follow a normal distribution with median (range) and the scale ones with normal distribution with mean (SD). Normality was tested through histograms and Kolmogorov-Smirnov test. According to these characteristics of variables, the comparisons between both protocols were conducted with Pearson's chi test[2] or Fisher's Exact Test, Mann-Whitney U test, or Student's t test, respectively. All these tests were bilateral, with a p≤0.05 level of significance, and all relevant calculations were conducted with the SPSS statistical program by IBM Co® 21.0 in the Windows XP Professional operating system.

Results

There were 83 patients included in the study in total: 34 patients according to Protocol 1 and 49 patients according to Protocol 2. Table 1 shows the basal characteristics of both groups; no statistically significant differences were found in any of the characteristics evaluated.

Table 2 describes the characteristics regarding basiliximab administration and TAC initiation with both protocols. In the arm of patients who received basiliximab according to Protocol 2, 2 patients were lost due to premature exitus before their second basiliximab administration. The majority of patients included in the study period 2 received basiliximab (93.6% vs. 41%). It is worth highlighting that with Protocol 1, there was a higher proportion of patients who received two doses (78.6% vs. 43.2%). The median number of days for TAC introduction was 4 for Protocol 2 vs. 1 for Protocol 1. Table 2 shows in detail the differences in the initiation of TAC administration according to the protocol and the number of basiliximab doses administered. It can be observed that when Protocol 1 was used, TAC

Table 1. Characteristics of the patient sample in the study "Clinical-economic impact of the change of protocol for use of basiliximab in liver transplant"

Patient characteristics	Protocol 1 (n = 34)	Protocol 2 (n = 49)	p-value
Age[1] in years	57 (8)	54 (9)	0.242
Male gender[2]	26 (77)	39 (80)	0.790
Hepatocellular carcinoma[2]	12 (35)	14 (29)	0.631
Hepatitis C[2]	12 (35)	14 (29)	0.631
Meld Index[1]	16 (6)	15 (4)	0.627
Basal renal function in mL/min/1.73 m[2] [1]	80 (33)	71 (25)	0.211
Pre-transplant diabetes[2]	12 (35)	14 (30)	0.636
Ascites refractory to treatment with diuretics[2]	6 (18)	13 (28)	0.426
Patients with risk factors [2]	20 (61)	28 (57)	0.885
No. of medications at discharge[3]	11 (8-14)	11 (6-17)	0.818

Protocol 1: Administration of basiliximab only to patients with risk factors. Protocol 2: Administration of first dose of basiliximab to all patients.
[1]Mean (SD) compared with Student's t test for independent samples. [2]Absolute frequency (relative frequency) compared with Pearson's chi-square test. [3]Median (range) compared with Mann-Whitney's U test.

Table 2. Characteristics of the use of basiliximab in the patients included in the study "Clinical-economic impact of the change of protocol for use of basiliximab in liver transplant"

Characteristic of the use of basiliximab	Protocol 1 (n = 34)	Protocol 2 (n = 47)	p-value
Dosis of basiliximab administered[1]	27	67	0.002
Patients who received basiliximab[2]	14 (41)	44 (94)	<0.001
Doses of basiliximab/patient[3]	0.8 (0.2)	1.4 (0.1)	0.003
Doses administered of basiliximab/patient[3]	1.9 (0.1)	1.5 (0.1)	0.014
Days of tacrolimus initiation[4]	1 (1-7)	4 (0-12)	0.004
Days of tacrolimus initiation without basiliximab[4]	1 (1-1)	1 (1-1)	0.999[5]
Days of tacrolimus initiation with 1 dose of basiliximab[4]	5 (3-6)	3 (0-6)	0.326[5]
Days of tacrolimus initiation with 2-3 doses of basiliximab[4]	5 (4-7)	6 (2-12)	0.108[5]
Patients with 1 dose of basiliximab[2]	2 (14)	23 (52)	0.044
Patients with 2 doses of basiliximab[2]	11 (79)	19 (43)	
Patients with 3 doses of basiliximab[2]	1 (7)	2 (5)	

Doses of basiliximab administered	Tacrolimus initiation[6]					
	Protocol 1 (n = 34)			Protocol 2 (n = 47)		
	Within range[7]	Early	Delayed	Within range[7]	Early	Delayed
0	20 (100)	—	—	3 (100)	—	—
1	1 (50)	—	1 (50)	14 (61)	6 (26)	3 (13)
2-3	10 (83)	2 (17)	—	14 (67)	3 (14)	4 (19)
Total	31 (91)	2 (6)	1 (3)	31 (66)	9 (19)	7 (15)

Protocol 1: Administration of basiliximab only to patients with risk factors. Protocol 2: Administration of first dose of basiliximab to all patients.
[1]Absolute frequencies compared with Pearson's chi-square test. [2]Absolute frequency (relative frequency) compared with Pearson's chi-square test. [3]Mean (SD) compared with Student's t test for independent samples. [4]Median (range) compared with Mann-Whitney's U test. [5]Lack of significance caused by overlapping time intervals. [6]Number of patients (% of the total number of basiliximab doses administered). [7]Within range: Day 1 if 0 doses of basiliximab; days 3-4 if 1 dose of basiliximab; days 5-7 if 2 doses of basiliximab.

introduction could be conducted as previously determined; when 2-3 doses of basiliximab were used, 17% of patients could initiate TAC treatment earlier than expected. However, under Protocol 2, protocol compliance when one and two doses of basiliximab were administered was of 61% and 67%, respectively. It is worth highlighting that 26% of patients received one dose of basiliximab and had TAC initiated before the established period of 3-4 days. This situation was observed at a lower extent (14%) when two doses of basiliximab were administered.

Health outcomes are shown in table 3; no statistically significant differences have been found in any of the variables evaluated: stay at ICU and for the transplant episode, hypertension and diabetes after the transplant, renal function with GFR < 60 mL/min, mortality in the immediate period after the transplant (before hospital discharge), at three months and at one year.

Table 3 also shows the evolution of renal function considering different changes: basal value compared with discharge from ICU, basal value compared with hospital discharge; basal value compared with one year after transplantation, and the GFR presented at the time of hospital discharge compared with the GFR one year after the transplant. In all cases, no statistically significant differences were found.

Table 4 shows economic outcomes, in terms of direct costs associated with a higher use of basiliximab at the change of regimen. It can be observed that there was a high percentage of patients without risk factors who received at least one dose of basiliximab (90% vs. 0%). The cost incurred

for basiliximab administration under Protocol 2 in patients without risk factors was 1,464 € per patient. Considering that 43% of patients included in Protocol 2 did not present any risk factors before transplantation, and accepting 34 liver transplants conducted in adults in our center in one year, the incremental difference in costs was estimated in 21,400 €.

Discussion

One of the studies showing benefit with the protocol for universal administration of basiliximab was ReSpECT[3], a prospective, multicenter, randomized and open study which excluded patients with renal impairment before transplantation, and which showed a significant improvement in renal function by 10 mL/min at 52 weeks in the induction group; however, this difference in patients with GFR > 60 mL/min could lack any clinical relevance, while in our study we took into account the value at baseline and at discharge of renal function, differentiating those patients with GFR above or below 60 mL/min, so that no clinically relevant differences were found. The study by Cai J. showed that induction improves the prognosis for graft and patient in renal, liver (43,407 patients) and lung transplant, in a highly significant way, at 3 months, 1 year and 5 years[13]. In the case of liver transplant, survival improved by approximately 3-4%, and this was difficult to find in our sample possibly due to the sample size, as well as differences in the follow-up period. Likewise, in the retrospective study of the register

Table 3. Variables of health outcomes and clinical in the patients of the study "Clinical-economic impact of the change of protocol for use of basiliximab in liver transplant"

Health outcomes	Protocol 1 (n = 34)	Protocol 2 (n = 49)	p-value
Stay in days at the Intensive Care Unit[1]	3 (1-12)	3 (1-20)	0.681
Overall stay in days[1]	23 (10-62)	22 (11-137)	0.636
Patients with hypertension after the OLT[2]	8 (24)	13 (30)	0.614
Patients with diabetes after the OLT[2]	17 (50)	16 (36)	0.255
Patients with GFR < 60 mL/min/1.73 m² per year vs. baseline[2]	3 (10)	6 (15)	0.722
Patients with GFR < 60 mL/min/1.73m2 per year after OLT[2]	6 (19)	10 (25)	0.775
Patients with GFR < 60 mL/min at discharge vs. baseline[2]	2 (6)	4 (9)	0.689
Mortality post-OLT and before hospital discharge[2]	0 (0)	5 (10)	0.075
Mortality at 3 months after OLT[2]	1 (3)	6 (13)	0.120
Mortality at 1 year after OLT[2]	3 (9)	7 (15)	0.412

Changes in renal function (ml/min/1.73 m²)		Protocol 1 (n = 34)	Protocol 2 (n = 49)	p-value
From admission to Hospital ICU	Basal GFR > 60 ICU > 60	23 (70)	27 (63)	
	Basal GFR > 60 ICU < 60	0 (0)	2 (5)	
	Basal GFR < 60 ICU > 60	6 (18)	8 (19)	0.5151
	Basal GFR < 60 ICU < 60	4 (12)	6 (14)	
From admission to discharge	Basal GFR > 60 Discharge > 60	20 (61)	26 (61)	
	Basal GFR > 60 Discharge < 60	3 (9)	3 (7)	
	Basal GFR < 60 Discharge > 60	5 (15)	7 (16)	0.9102
	Basal GFR < 60 Discharge < 60	5 (15)	7 (16)	
From admission to one year after transplantation	Basal GFR > 60 Year > 60	19 (63)	22 (56)	
	Basal GFR > 60 Year < 60	3 (10)	4 (10)	
	Basal GFR < 60 Year > 60	4 (13)	6 (15)	0.7351
	Basal GFR < 60 Year < 60	4 (13)	7 (18)	
From discharge to one year after transplantation	GFR Discharge > 60 Year > 60	20 (67)	25 (63)	
	GFR Discharge > 60 Year < 60	5 (17)	5 (13)	
	GFR Discharge < 60 Year > 60	3 (10)	3 (8)	0.2831
	GFR Discharge < 60 Year < 60	2 (7)	7 (18)	

Protocol 1: Administration of basiliximab only to patients with risk factors. Protocol 2: Administration of first dose of basiliximab to all patients.
OLT: orthotopic liver transplant. [1]Median (range) compared with Mann-Whitney's U test. [2]Absolute frequency (relative frequency) compared with Pearson's chi-square test.

Table 4. Economic outcomes from the study "Clinical-economic impact of the change of protocol for use of basiliximab in liver transplant"

Aspect evaluated	Administration and costs	
	Protocol 1 (*n* = 34)	Protocol 2 (*n* = 47)
Basiliximab doses used[1]	27	67
Basiliximab doses administered to patients with risk factors previous to transplantation[2]	27 (100)	43 (64)
Patients without risk factors previous to transplantation who did not receive basiliximab[2]	14 (100)	2 (10)
Patients without risk factors previous to transplantation who received 1 dose of basiliximab[2]	0 (0)	11 (58)
Patients without risk factors previous to transplantation who received 2-3 doses of basiliximab[2]	0 (0)	6 (32)
Theoretical doses administered to patients without risk factors[1]	0	24
Cost in € of the administration of basiliximab to patients without risk factors	0	27,823.00
Cost in € per patient of the administration of basiliximab to patients without risk factors	0	**1,464.00**

Protocol 1: Administration of basiliximab only to patients with risk factors. Protocol 2: Administration of first dose of basiliximab to all patients.
Risk factors: renal impairment, diabetes, or refractory ascites previous to transplantation [1]Absolute frequency. [2]Absolute frequency (relative frequency).

of transplanted patients between 2002 and 2009, with and without hepatocellular carcinoma, where different immunosuppressant regimens were evaluated, and 14,658 patients were included in total, overall survival was analyzed at long term (3 and 5 years), though it was significant with anti-CD25 induction only in the hepatocellular carcinoma arm[12]. Other studies demonstrated a lower incidence of rejection confirmed by biopsy; this was not collected in our study population due to the difficult access to biopsy results[13]. A systematic review and meta-analysis of 18 controlled studies, of which only 13 were randomized, demonstrated a significantly lower incidence of acute rejection, including resistance to steroids, with induction; as well as a non-significant trend towards better survival, lower incidence of diabetes, and lower risk of renal dysfunction; however, no differences were found in terms of graft and patient survival, and therefore there is coincidence with our results in terms of survival data, except for the fact that we did not find any differences in complications after the transplant such as diabetes or renal function deterioration[15]. The study by Chih-Che Lin *et al.* included 45 patients split into two arms, with the objective to determine if there was an improvement in renal function in those patients who received induction therapy with basiliximab; statistically significant differences were found three months after the transplant, unlike in our study, where we conducted follow-up for 52 weeks after the transplant[10].

Other studies, coinciding with our results, did not find any statistically significant differences in the reduction of the incidence of acute rejection episodes, and in improving the graft function, though they measured survival at long term (36 weeks)[16].

The recommendations from the 5th Consensus Meeting by the Spanish Society of Liver Transplant, with conclusions published by the end of 2015, coincide with our results, and only recommend induction in patients with renal impairment before transplantation or in patients at high risk of renal impairment after the transplant, without reaching a consensus about its universal use[17]. On the contrary, the European Guidelines for Liver Transplant published at the start of 2016 recommend, with Recommendation Level I, the use of IL-2R antibodies and TAC at lower doses and delayed initiation together with MMF and steroids, because it is safe and improves renal function significantly, though some concern is expressed about the high cost of IL-2R, an important aspect that we took into account in our study[18]. The American Guidelines for Clinical Practice in adults who have undergone OLT describes the use of these agents[19].

The majority of the pharmacoeconomic studies published has been conducted using basiliximab as induction in renal transplant patients, in two cases using dual therapy as control arm (corticosteroids + cyclosporine), although the conclusion seems to be that using basiliximab as induction in renal transplant is cost-effective because there is a reduction in hospital stay and a lower rate of acute rejection[20-22]. In an editorial published in 2002, Ryutaro Hirose explained that cost represents a barrier for the routine use of IL-2R in liver transplant, and that this additional cost might not be justified, unless a significantly reduction is demonstrated in rejection rates and readmissions, aspects that have not been evaluated in

our study[22] . A search was conducted in Pubmed using the following terms in English: "pharmacoeconomic", "liver transplantation" and "basiliximab"; only one study was found, in a 49-patient pediatric population, comparing an arm that received TAC + basiliximab, corticosteroid-free, vs. standard therapy with corticosteroids + TAC; the conclusion was that medical costs were similar in both arms; however, neither the study population nor the immunosuppressant therapy used could be extrapolated[24].

Our study presents some limitations: one could be derived of the sample size, because we have selected transplanted patients since 2013, given that data collection before this date was not possible. Other potential bias is the lack of evaluation of the development of steroid-resistant acute rejection, an aspect that could be relevant, as well as the time used to reach therapeutic levels of TAC. The cost of purchasing TAC was not included, because it was considered irrelevant, and a high variability of dosing was found. The follow-up period was of one year after OLT, but it would be interesting to assess the long-term evolution of renal function, such as has been evaluated in other series.

In our sample, the lack of improvement of renal function observed could be associated with the initiation of TAC before the time initially stated in the protocol; therefore, this was considered a critical point. These data were submitted to the liver transplant team, and the conclusion was that it was necessary to increase adherence to protocol regarding TAC initiation.

Taking into account limitations and bias, we consider that the results obtained do not confirm the objectives expected from the change of the protocol, even at the higher cost incurred. As can be deduced from our study and the new consensus guidelines, basiliximab would play an important role in patients with high creatinine levels or at risk of presenting renal impairment.

There is limited evidence published about the use of basiliximab in OLT in terms of quality, as there is high heterogeneity in the populations selected; therefore, it would be necessary to conduct randomized and blind clinical trials, preferably independent, in order to help in making clinical decisions.

Funding

Conflict of interests

No conflict of interests.

Contribution to scientific literature

The relevance of our study is determined by the comparison between two different protocols of use for basiliximab in liver transplant in adult population; it aims to confirm if the use of basiliximab is cost-effective in all patients or only in those with risk factors, while other published studies compare a regimen with or without basiliximab.

Bibliography

1. Serrano Aullóa MT, Parra Moncasi E, Lorente Pérez S. Inmunosupresión en el trasplante hepático: pautas renoprotectoras. Gastroenterol Hepatol. 2011;34(6):422-7. DOI: 10.1016/j.gastrohep.2010.12.009

2. Ramírez CB, Bozdin A, Frank A, Maley W, Doria C. Optimizing use of Basiliximab in liver transplantation. Transplant Research and Risk Management. 2010;2:1-10.

3. Neuhaus P, Clavien PA, Kittur D, Salizzoni M, Rimola A, Abeywickrama K, *et al.* Improved Treatment Response with Basiliximab Immunoprophylaxis After Liver Transplantation: Results From a Double-Blind Randomized Placebo-Controlled Trial. Liver Transpl. 2002;8:132-42.

4. Neuberger JM, Mamelok RD, Neuhaus P, Pirenne J, Samuel D, Isoniemi H, *et al.* Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. Am J Transplant. 2009;9:327-36.

5. Toso C, Merani S, Bigam DL, Shapiro AM, Kneteman NM. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology. 2010;51:1237-43.

6. Onrust SV, Wiseman LR. Basiliximab. Drugs. 1999;57:207-13.

7. Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP. Randomised trial of Basiliximab vs placebo for control of acute cellular rejection in renal alllograft recipients. Lancet. 1997;350:1193-8.

8. Nelson DR, Soldevila-Pico C, Reed A, Abdelmalek MF, Hemming AW, Van der Werf J, *et al.* Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. Liver Transpl. 2001;7:1064-70.

9. Sellers MT, Mcguire BM, Haustein SV, Bynon JS, Hunt SL, Eckhoff DE. Two-dose daclizumab induction therapy in 209 liver transplants: a single-center analysis. Transplantation. 2004;78:1212-7.

10. Chih-Che L, Feng-Rong Ch, Chih-Hsiung L, Chih-Chi W, Yaw-Sen Ch, Yueh-Wei L, *et al.* The Renal-Sparing Efficacy of Basiliximab in Adult Living Donor Liver Transplantation. Liver Transpl. 2005;11:1258-64.

11. Varo E, López A, Castroagudin JF, Delgado M, Conde R, Ferrer E, *et al.* Alternative immunosuppression for acute renal failure in liver transplantation: role of ultra-low dose of tacrolimus and Basiliximab. Transplant Proc. 2002;34:1533-4.

12. Vargas V, Ortiz M. Modelos pronósticos en la cirrosis hepática. El modelo MELD. Editorial. Gastroenterol Hepatol. 2003;26(4):257-9.

13. Cai J, Terasaki PI. Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: an analysis of United Network for Organ Sharing registry data. Transplantation. 2010;90:1511-5.

14. Otero A, Varo E, de Urbina JO, Martín-Vivaldi R, Cuervas-Mons V, González-Pinto I, *et al.* A Prospective Randomized Open Study in Liver Transplant Recipients: Daclizumab, Mycophenolate Mofetil, and Tacrolimus Versus Tacrolimus and Steroids. Liver Trans. 2009;15:1542-52.

15. Goralczyk AD, Hauke N, Bari N, Tsui TY, Lorf T, Obed A. Interleukin 2 receptor antagonists for liver transplant recipients: a systematic review and meta-analysis of controlled studies. Hepatology. 2011;54:541-54.

16. Schmeding M, Sauer IM, Kiessling A, Pratschke J, Neuhaus R, Neuhaus P, *et al.* Influence of Basiliximab induction therapy on long term outcome after liver transplantation, a prospectively randomised trial. Ann Transplant. 2007;12(3):15-21.

17. Pardo F, Pons JA, Briceño J. V Reunión de Consenso de la Sociedad Española de Trasplante Hepático sobre receptores de riesgo elevado, escenarios actuales de inmunosupresión y manejo del hepatocarcinoma en espera de trasplante. Cir Esp. 2015;93(10):619-37.

18. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Liver transplantation. J Hepatol. 2016;64:433-85. DOI: https://doi.org/10.1016/j.jhep.2015.10.006

19. Lucey MR, Terrault N, Ojo L, Hay JE, Neuberger J, Blumberg E, *et al.* Long-Term Management of the Successful Adult Liver Transplant: 2012 Practice Guideline by AASLD and the American Society of Transplantation. Liver Transpl. 2013;19:3-26.

20. Lorber MI, Fastenau J, Wilson D, DiCesare J, Hall ML. A prospective economic evaluation of Basiliximab (Simulect) therapy following renal transplantation. Clin Transplant. 2000;14:479-85.

21. Keown PA, Balshaw R, Krueger H, Baladi JF. Economic analysis of Basiliximab in renal transplantation. Transplantation. 2001;71:1573-9.

22. Walters SJ, Whitfield M, Akerhurst RL, Chilcott JB. Economic implications of the use of Basiliximab in addition to triple immunosuppressive therapy in renal allograft recipients. Pharmacoeconomics. 2003;21:129-38.

23. Hirose R. Pros and Cons of Using Interleukin-2 Receptor Antibodies in Liver Transplant Recipients. Liver Transpl. 2002;8(2):143-5. DOI: 10.1053/jlts.2002.31384

24. Gras JM, Gerkens S, Beguin C, Janssen M, Smets F, Otte JB, *et al.* Steroid-free, tacrolimus-basiliximab immunosuppression in pediatric liver transplantation: clinical and pharmacoeconomic study in 50 children. Liver Transpl. 2008;14(4):469-77. DOI: 10.1002/lt.21397